Department of Radiation Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Clin Transl Oncol. 2012 Feb;14(2):109-15. doi: 10.1007/s12094-012-0769-3.
We present the results of a prospective ten-year follow-up study to prove the effectiveness of a single fraction of 192-Ir high-dose-rate (HDR) brachytherapy (BT) as a boost.
Between 1999 and 2000, 84 consecutive patients with invasive breast carcinoma, with over 4 mm free margins after conservative surgery, were treated. All cases were stages T1-2, except for one case, a stage T3, 81% pN0, 19% pN1-2. Chemotherapy was used in 47% and hormonal therapy in 87%. Whole breast external beam radiotherapy (46 Gy) was followed 1-2 weeks later by an implant with metallic needles. A 7 Gy single dose of HDR BT to the 90% isodose line was delivered on an outpatient basis. Dosimetry was performed theoretically. This technique is called FAST-boost because the whole treatment is delivered in about two hours.
With a median follow-up of 120 months, three patients relapsed in the margin of the implant and two in a different quadrant (5/84, 6%). Actuarial local control at five and ten years was 98.5% and 95.6%. Overall survival was 92.7% and 90.2%, and disease-free survival 90.2% and 79.9%. Cosmetic results were good or excellent in 92.5%.
A single-fraction HDR boost with rigid needles (FAST-boost) is a good, quick, simple technique when surgical margins are free.
我们呈现了一项前瞻性十年随访研究的结果,以证明单次 192Ir 高剂量率(HDR)近距离放疗(BT)作为推量的有效性。
在 1999 年至 2000 年期间,84 例浸润性乳腺癌患者接受了治疗,这些患者在接受保乳手术后有超过 4 毫米的无肿瘤切缘。所有病例均为 T1-2 期,除了 1 例 T3 期、81%的 pN0、19%的 pN1-2 期。47%的患者接受了化疗,87%的患者接受了激素治疗。在 1-2 周后,所有患者接受了全乳外照射放疗(46Gy),随后进行金属针植入。在门诊患者的基础上,给予 90%等剂量线 7Gy 的单次 HDR BT。进行理论剂量学评估。该技术称为 FAST-boost,因为整个治疗过程大约需要两小时。
中位随访 120 个月后,3 例患者在植入物边缘复发,2 例患者在不同象限复发(5/84,6%)。5 年和 10 年的局部控制率分别为 98.5%和 95.6%,总生存率分别为 92.7%和 90.2%,无病生存率分别为 90.2%和 79.9%。92.5%的患者美容效果良好或优秀。
当手术切缘无肿瘤时,单次 HDR 推量加刚性针(FAST-boost)是一种快速、简便、有效的技术。